Publicacións (97) Publicacións de Ana Fernández Montes

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  5. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  6. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108

  7. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

  8. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

  9. SEOM 2023 clinical guidelines

    Clinical and Translational Oncology

  10. State of the scientific evidence and recommendations for the management of older patients with gastric cancer

    Journal of Geriatric Oncology, Vol. 15, Núm. 3

2023

  1. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study

    Oncologist, Vol. 28, Núm. 11, pp. 986-995

  2. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

  3. Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer

    Psycho-Oncology, Vol. 32, Núm. 11, pp. 1694-1701

  4. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802

  5. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  6. Mental Adjustment, Functional Status, and Depression in Advanced Cancer Patients

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 4

  7. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  8. Psychological factors and prognostic communication preferences in advanced cancer: multicentre study

    BMJ Supportive and Palliative Care, Vol. 13, Núm. e3, pp. E1342-E1350

  9. Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study

    Cancers, Vol. 15, Núm. 18

  10. SEOM 2022 clinical guidelines

    Clinical and Translational Oncology